Abstract
AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). Patients with previously untreated, locally advanced, or metastatic NSCLC (squamous cell cancer or adenocarcinoma) in good performance status and with preserved major organ functions were enrolled in the study. The study was an open-label phase I study with planned cohorts of three patients per dose level of AXL1717 (215, 290, and 390 mg BID). In total, 12 patients were enrolled in the study, and of these, two were prematurely excluded. AXL1717 was administered at one dose level, 215 mg BID. A total number of 81 unique adverse events were reported. Bone marrow toxicity was reported in 10 out of 12 patients, and this organ class showed the largest number of related events. AXL1717 in combination with gemcitabine HCl and carboplatin is a possible treatment approach in previously untreated, locally advanced, or metastatic non-small cell lung cancer. However, due to the bone marrow toxicity profile shown in the ...Continue Reading
References
Jan 20, 2004·Cancer Research·Ada GirnitaMagnus Axelson
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christer SederholmSulochana R Gawande
Nov 29, 2007·Journal of the National Cancer Institute·Caroline McNeil
Nov 30, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Elizabeth A JohnsonEdith A Perez
Jul 25, 2009·Journal of Cell Science·Karen E Gascoigne, Stephen S Taylor
Aug 12, 2010·Acta Oncologica·Simon EkmanMichael Bergqvist
Sep 13, 2011·Cancer Treatment Reviews·Giorgio V Scagliotti, Silvia Novello
Nov 26, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Joseph TreatMark A Socinski
Jan 30, 2013·Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu·Jin-Ji YangYi-Long Wu
Aug 27, 2013·Lancet·Martin ReckKlaus F Rabe
May 13, 2014·Targeted Oncology·Josep TaberneroJosé Baselga
Aug 2, 2014·Journal of Cancer Research and Clinical Oncology·M Teresa Agulló-OrtuñoJosé A López Martín
Aug 15, 2014·Journal of Clinical Pathology·T N TranW A Cooper
Aug 29, 2014·Molecular Carcinogenesis·Qi ZhangMing You
Citations
Jul 26, 2019·Journal of Hematology & Oncology·Bhawana GeorgeHesham M Amin
Oct 27, 2017·Scientific Reports·Christabel WilsonJohn C Ashton
Sep 24, 2016·Oncotarget·Deeksha VishwamitraHesham M Amin
Nov 5, 2019·Frontiers in Oncology·Xuan ZhuXing Niu
Nov 24, 2020·Frontiers in Cell and Developmental Biology·Alyssa J CozzoStephen D Hursting